The cell-culture-based vaccine is directed against avian flu virus H5N1 and was jointly developed with IHI and UMN where Astellas had exclusive rights to sell the product in Japan.
Astellas news release January 12, 2017
Astellas stops development of H5N1 influenza vaccine ASP7373 and 7374